AMX-883

AMX-883 is a potent, selective, and orally available small molecule targeted protein degrader developed for the treatment of acute myeloid leukaemia (AML). It acts as a broad-acting, pro-differentiation agent capable of inducing almost complete degradation of BRD9 within two hours of treatment, while retaining high selectivity over other bromodomain-containing proteins. AMX-883 employs Amphista’s proprietary Targeted Glue technology, recruiting the DCAF16 E3 ligase to degrade BRD9—a novel mechanism of action distinct from cereblon- or VHL-based PROTACs. Preclinical data support its efficacy across diverse AML karyotypes and demonstrate in vivo activity, including in patient-derived xenograft models[1][2][4].